Ezetimibe and bile acid sequestrants: Impact on lipoprotein metabolism and beyond

Current Opinion in Lipidology

Volumn 24, Issue 3, 2013, Pages 227-232

  Couture, Patrick ^a   Lamarche, Benoît ^a  

^a UNIVERSITÉ LAVAL   (Canada)

Author keywords

Bile acid sequestrants; Bile acids; Cholesterol absorption; Dyslipidemia; Ezetimibe

Indexed keywords

APOLIPOPROTEIN; APOLIPOPROTEIN B100; ATORVASTATIN; BILE ACID SEQUESTRANT; CHOLESTEROL; CHOLESTEROL 7ALPHA MONOOXYGENASE; COLESEVELAM; COLESTIPOL; COLESTYRAMINE; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN; LIVER X RECEPTOR; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MESSENGER RNA; METFORMIN; SIMVASTATIN; STEROL REGULATORY ELEMENT BINDING PROTEIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; FAMILIAL HYPERCHOLESTEROLEMIA; GENE EXPRESSION; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; INTESTINE ABSORPTION; JEJUNUM; LIPOPROTEIN METABOLISM; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; REVIEW; TRIACYLGLYCEROL BLOOD LEVEL;

ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEINS; AZETIDINES; BILE ACIDS AND SALTS; CARDIOVASCULAR DISEASES; CHOLESTEROL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; GENE EXPRESSION REGULATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTESTINAL ABSORPTION; LIPID METABOLISM;

EID: 84880133958     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0b013e3283613a55     Document Type: Review

References (56)

1. Levy E, Spahis S, Sinnett D, et al. Intestinal cholesterol transport proteins: an update and beyond. Curr Opin Lipidol 2007; 18:310-318. (Pubitemid 46743056)
2. Out C, Groen AK, Brufau G. Bile acid sequestrants: more than simple resins. Curr Opin Lipidol 2012; 23:43-55.
3. Xie C, Zhou ZS, Li N, et al. Ezetimibe blocks the internalization of NPC1L1 and cholesterol in mouse small intestine. J Lipid Res 2012; 53:2092-2101.
4. Xie C, Turley SD, Dietschy JM. ABCA1 plays no role in the centripetal movement of cholesterol from peripheral tissues to the liver and intestine in the mouse. J Lipid Res 2009; 50:1316-1329.
5. Spady DK, Dietschy JM. Sterol synthesis in vivo in 18 tissues of the squirrel monkey, guinea pig, rabbit, hamster, and rat. J Lipid Res 1983; 24:303-315. (Pubitemid 13090847)
6. Spady DK, Bilheimer DW, Dietschy JM. Rates of receptor-dependent and-independent low density lipoprotein uptake in the hamster. Proc Natl Acad Sci U S A 1983; 80:3499-3503. (Pubitemid 13060191)
7. Spady DK, Turley SD, Dietschy JM. Receptor-independent low density lipoprotein transport in the rat in vivo. Quantitation, characterization, and metabolic consequences. J Clin Invest 1985; 76:1113-1122. (Pubitemid 16225560)
8. Brown MS, Goldstein JL. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 1997; 89:331-340. (Pubitemid 27220877)
9. Engelking LJ, Kuriyama H, Hammer RE, et al. Overexpression of Insig-1 in the livers of transgenic mice inhibits SREBP processing and reduces insulin-stimulated lipogenesis. J Clin Invest 2004; 113:1168-1175. (Pubitemid 38544102)
10. Shimomura I, Bashmakov Y, Shimano H, et al. Cholesterol feeding reduces nuclear forms of sterol regulatory element binding proteins in hamster liver. Proc Natl Acad Sci U S A 1997; 94:12354-12359. (Pubitemid 27492532)
11. Clader JW. The discovery of ezetimibe: a view from outside the receptor. J Med Chem 2004; 47:1-9. (Pubitemid 38040483)
12. Garcia-Calvo M, Lisnock J, Bull HG, et al. The target of ezetimibe is Niemann-Pick C1-Like 1(NPC1L1). Proc Natl Acad Sci U SA 2005; 102:8132-8137. (Pubitemid 40800055)
13. Engelking LJ, McFarlane MR, Li CK, Liang G. Blockade of cholesterol absorption by ezetimibe reveals a complex homeostatic network in entero-cytes. J Lipid Res 2012; 53:1359-1368.
14. Telford DE, Sutherland BG, Edwards JY, et al. The molecular mechanisms underlying the reduction of LDL apoB-100 by ezetimibe plus simvastatin. J Lipid Res 2007; 48:699-708. (Pubitemid 46397473)
15. Valasek MA, Repa JJ, Quan G, et al. Inhibiting intestinal NPC1L1 activity prevents diet-induced increase in biliary cholesterol in Golden Syrian hamsters. Am J Physiol Gastrointest Liver Physiol 2008; 295:G813-G822.
16. Tilvis RS, Miettinen TA. Serum plant sterols and their relation to cholesterol absorption. Am J Clin Nutr 1986; 43:92-97. (Pubitemid 16099791)
17. Matthan NR, Raeini-Sarjaz M, Lichtenstein AH, et al. Deuterium uptake and plasma cholesterol precursor levels correspond as methods for measurement of endogenous cholesterol synthesis in hypercholesterolemic women. Lipids 2000; 35:1037-1044.
18. Rajaratnam RA, Gylling H, Miettinen TA. Independent association of serum squalene and noncholesterol sterols with coronary artery disease in post-menopausal women. J Am Coll Cardiol 2000; 35:1185-1191. (Pubitemid 30206893)
19. Cuchel M, Schaefer EJ, Millar JS, et al. Lovastatin decreases de novo cholesterol synthesis and LDL Apo B-100 production rates in combined- hyperlipidemic males. Arterioscler Thromb Vasc Biol 1997; 17:1910-1917. (Pubitemid 28057089)
20. Parhofer KG, Barrett PH, Dunn J, Schonfeld G. Effect of pravastatin on metabolic parameters of apolipoprotein B in patients with mixed hyperlipo-proteinemia. Clin Investig 1993; 71:939-946. (Pubitemid 23327483)
21. Watts GF, Barrett PH, Ji J, et al. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome. Diabetes 2003; 52:803-811. (Pubitemid 36323589)
22. Tremblay AJ, Lamarche B, Hogue JC, Couture P. Effects of ezetimibe and simvastatin on apolipoprotein B metabolism in males with mixed hyperlipide-mia. J Lipid Res 2009; 50:1463-1471.
23. Ballantyne CM, Houri J, Notarbartolo A, et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation 2003; 107:2409-2415. (Pubitemid 36605221)
24. Davidson MH, McGarry T, Bettis R, et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol 2002; 40:2125-2134. (Pubitemid 36005898)
25. Leiter LA, Betteridge DJ, Farnier M, et al. Lipid-altering efficacy and safety profile of combination therapy with ezetimibe/statin vs. statin monotherapy in patients with and without diabetes: an analysis of pooled data from 27 clinical trials. Diabetes Obes Metab 2011; 13:615-628.
26. Kotani K, Sakane N, Taniguchi N. Effect of ezetimibe on remnant-like particle cholesterol in subjects with metabolic syndrome. Med Princ Pract 2012; 21:134-138.
27. Yunoki K, Nakamura K, Miyoshi T, et al. Ezetimibe improves postprandial hyperlipemia and its induced endothelial dysfunction. Atherosclerosis 2011; 217:486-491.
28. Masuda D, Nakagawa-Toyama Y, Nakatani K, et al. Ezetimibe improves postprandial hyperlipidaemia in patients with type IIb hyperlipidaemia. Eur J Clin Invest 2009; 39:689-698.
29. Sandoval JC, Nakagawa-Toyama Y, Masuda D, et al. Molecular mechanisms of ezetimibe-induced attenuation of postprandial hypertriglyceridemia. J Atheroscler Thromb 2010; 17:914-924.
30. Lee SH, Park S, Kang SM, etal. Effectofatorvastatinmonotherapyandlow-dose atorvastatin/ezetimibe combination on fasting and postprandial triglycerides in combined hyperlipedemia. J Cardiovasc Pharmacol Ther 2012; 17:65-71.
31. Bozzetto L, Annuzzi G, Corte GD, et al. Ezetimibe beneficially influences fasting and postprandial triglyceride-rich lipoproteins in type 2 diabetes. Atherosclerosis 2011; 217:142-148.
32. Chan DC, Watts GF, Gan SK, et al. Effect of ezetimibe on hepatic fat, inflammatory markers, and apolipoprotein B-100 kinetics in insulin-resistant obese subjects on a weight loss diet. Diabetes Care 2010; 33:1134-1139.
33. Grundy SM, Ahrens EH Jr, Salen G. Interruption of the enterohepatic circulation of bile acids in man: comparative effects of cholestyramine and ileal exclusion on cholesterol metabolism. J Lab Clin Med 1971; 78:94-121.
34. Herrema H, Meissner M, van Dijk TH, et al. Bile salt sequestration induces hepatic de novo lipogenesis through farnesoid X receptor-and liver X receptor alpha-controlled metabolic pathways in mice. Hepatology 2010; 51:806-816.
35. Bays H, Dujovne C. Colesevelam HCl: a nonsystemic lipid-altering drug. Expert Opin Pharmacother 2003; 4:779-790. (Pubitemid 36622207)
36. Corsini A, Windler E, Farnier M. Colesevelam hydrochloride: usefulness of a specifically engineered bile acid sequestrant for lowering LDL-cholesterol. Eur J Cardiovasc Prev Rehabil 2009; 16:1-9.
37. Donovan JM, Stypinski D, Stiles MR, et al. Drug interactions with colesevelam hydrochloride, a novel, potent lipid-lowering agent. Cardiovasc Drugs Ther 2000; 14:681-690. (Pubitemid 32217192)
38. Hou R, Goldberg AC. Lowering low-density lipoprotein cholesterol: statins, ezetimibe, bile acid sequestrants, and combinations: comparative efficacy and safety. Endocrinol Metab Clin North Am 2009; 38:79-97.
39. Davidson MH, Dillon MA, Gordon B, et al. Colesevelam hydrochloride (chole-stagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. Arch Intern Med 1999; 159:1893-1900. (Pubitemid 29424709)
40. Insull W Jr, Toth P, Mullican W, et al. Effectiveness of colesevelam hydro-chloride in decreasing LDL cholesterol in patients with primary hypercholes-terolemia: a 24-week randomized controlled trial. Mayo Clin Proc 2001; 76:971-982. (Pubitemid 32946008)
41. Rosenson RS. Colesevelam HCl reduces LDL particle number and increases LDL size in hypercholesterolemia. Atherosclerosis 2006; 185: 327-330.
42. Devaraj S, Autret B, Jialal I. Effects of colesevelam hydrochloride (WelChol) on biomarkers of inflammation in patients with mild hypercholesterolemia. Am J Cardiol 2006; 98:641-643. (Pubitemid 44233461)
43. Donovan JM, Von Bergmann K, Setchell KD, et al. Effectsofcolesevelam HC1 on sterol and bile acid excretion in patients with type IIa hypercholesterolemia. Dig Dis Sci 2005; 50:1232-1238. (Pubitemid 41184748)
44. Insull W Jr. Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: a scientific review. South Med J 2006; 99:257-273.
45. Watanabe M, Houten SM, Wang L, et al. Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J Clin Invest 2004; 113: 1408-1418. (Pubitemid 39071696)
46. Claudel T, Inoue Y, Barbier O, et al. Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression. Gastroenterology 2003; 125:544-555. (Pubitemid 36929436)
47. Claudel T, Sturm E, Kuipers F, Staels B. The farnesoid X receptor: a novel drug target? Expert Opin Investig Drugs 2004; 13:1135-1148. (Pubitemid 39242737)
48. Davidson MH. A systematic review of bile acid sequestrant therapy in children with familial hypercholesterolemia. J Clin Lipidol 2011; 5:76-81.
49. Davidson MH, Toth P, Weiss S, et al. Low-dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low-density lipoprotein cholesterol in patients with primary hypercholesterolemia. Clin Cardiol 2001; 24:467-474. (Pubitemid 32520218)
50. Hunninghake D, Insull W Jr, Toth P, et al. Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively. Atherosclerosis 2001; 158:407-416. (Pubitemid 32913651)
51. Knapp HH, Schrott H, Ma P, et al. Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia. Am J Med 2001; 110:352-360. (Pubitemid 32248724)
52. Bays H, Rhyne J, Abby S, et al. Lipid-lowering effects of colesevelam HCl in combination with ezetimibe. Curr Med Res Opin 2006; 22:2191-2200. (Pubitemid 44789984)
53. Yamakawa T, Takano T, Utsunomiya H, et al. Effect of colestimide therapy for glycemic control in type 2 diabetes mellitus with hypercholesterolemia. Endocr J 2007; 54:53-58. (Pubitemid 46481671)
54. Garg A, Grundy SM. Cholestyramine therapy for dyslipidemia in noninsulin-dependent diabetes mellitus. A short-term, double-blind, crossover trial. Ann Intern Med 1994; 121:416-422.
55. Goldberg RB, Rosenson RS, Hernandez-Triana E, et al. Initial combination therapy with metformin plus colesevelam improves lipoprotein particles in patients with early type 2 diabetes mellitus. J Clin Lipidol 2012; 6:318-324.
56. Marina AL, Utzschneider KM, Wright LA, et al. Colesevelam improves oral but not intravenous glucose tolerance by a mechanism independent of insulin sensitivity and beta-cell function. Diabetes Care 2012; 35:1119-1125.